Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

The purpose of this study is to characterize the pharmacokinetics (the way the body absorbs, distributes and eliminates the drug) of BMS 986165 given in the form of various prototypes of solid tablets to healthy participants.

Key facts

Study ID

NCT04249284

Run by

Bristol-Myers Squibb

People needed

18

Starts

2020-02-06

Expected to finish

2020-03-15

Last updated by the study team

2020-04-09

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• In the opinion of the investigator, a healthy participant is determined by having no clinically significant deviation from normal in medical history, physical examination,electrocardiograms, vital signs, and clinical laboratory determinations.
• Body weight >= 50 kg at screening
• Women and men must agree to follow specific methods of contraception, if applicable

You may not qualify if…

• Any major surgery, per investigator's discretion, within 4 weeks of study drug administration
• Inability to tolerate oral medication
• History of allergy to BMS-986165 or related compounds
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Quotient Sciences Miami — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.